Potential nondopaminergic drugs for Parkinson's disease

Adv Neurol. 2003;91:273-91.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antiparkinson Agents / adverse effects*
  • Basal Ganglia / metabolism
  • Basal Ganglia / pathology
  • Basal Ganglia / physiopathology
  • Drug Therapy, Combination
  • Humans
  • Levodopa / adverse effects
  • Models, Neurological
  • Neural Pathways / metabolism
  • Neural Pathways / pathology
  • Neural Pathways / physiopathology
  • Neurotransmitter Agents / agonists
  • Neurotransmitter Agents / antagonists & inhibitors
  • Neurotransmitter Agents / metabolism
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / metabolism
  • Parkinson Disease / physiopathology
  • Receptors, Neurotransmitter / agonists
  • Receptors, Neurotransmitter / antagonists & inhibitors
  • Receptors, Neurotransmitter / metabolism
  • Substantia Nigra / metabolism
  • Substantia Nigra / pathology
  • Substantia Nigra / physiopathology

Substances

  • Antiparkinson Agents
  • Neurotransmitter Agents
  • Receptors, Neurotransmitter
  • Levodopa